论文部分内容阅读
(2017-04-07)[2016-04-07]http://www.sfda.gov.cn/WS01/CL0051/171464.html近期,国家食品药品监督管理总局发布第七十四期《药品不良反应信息通报》,警示麦考酚类药品的生殖毒性风险。麦考酚类药品是免疫抑制剂,主要与环孢素及皮质类固醇合并使用,预防接受同种异体肾脏或肝脏移植患者发生急性排斥反应。麦考酚类药品主要包括麦考酚酸钠和吗替麦考酚酯。麦考酚类药品的生殖毒性风险持续引起各国监管部门的关注。
(2017-04-07) [2016-04-07] http://www.sfda.gov.cn/WS01/CL0051/171464.html Recently, the State Food and Drug Administration released the 74th issue of “Poor Drugs Response Information Bulletin ”alerting the risk of reproductive toxicity of mycophenolate drugs. Mycophenolate mofetil is an immunosuppressive agent that is used in combination with cyclosporine and corticosteroid to prevent acute rejection in allograft recipients with kidney or liver allograft. Mycophenolate drugs include mycophenolate mofetil and mycophenolate mofetil. The risk of reproductive toxicity of mycophenolate drugs continues to attract the attention of regulatory authorities in various countries.